Get notified of page updates

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. Sign up for our community newsletter to stay up to date on the latest hereditary cancer research.

How to Use Our Search and Enroll Tool

Search Results: Treatment + Endometrial Cancer (7 results)

Printer Friendly Page 1 through 7 of 7
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

Treatment
People with stage I endometrial cancer who are having a hysterectomy

Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.

Clinicaltrials.gov identifier: NCT05646316
More info
New Treatment  in People with Triple Negative Breast Cancer or Advanced Solid Tumors

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas

Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas

Clinicaltrials.gov identifier: NCT06022029
More info
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:

  • have a tumor marker known as microsatellite stable (MSS), OR
  • have been treated with and no longer respond to treatment with immunotherapy drugs known as immune checkpoint inhibitors.
Clinicaltrials.gov identifier: NCT05572684
More info
A Study of  Targeted Therapies for Patients With Recurrent Endometrial Cancer

Treatment
This study is for people with recurrent endometrial cancer

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.

 

Clinicaltrials.gov identifier: NCT04486352
More info
Testing an Immunotherapy in Patients with Advanced Solid Tumors

Treatment
Treatment study for people with advanced cancers

Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.

Clinicaltrials.gov identifier: NCT02628067
More info
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

Treatment
Cancer treatment study for people with advanced solid tumors

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Clinicaltrials.gov identifier: NCT02693535
More info
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

Clinicaltrials.gov identifier: NCT03607890
More info
Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
107 results
Clinical Trial Official Title
NCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies
NCT05051722 Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT05039801 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT04514692 Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT05819892 Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT03682289 Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05086692 A Beta-only IL-2 ImmunoTherapY Study
NCT06253494 Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT05797831 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05591131 Genetic Testing in African Americans
NCT05123482 A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT05036681 A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT04319757 ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT03876860 An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
NCT04104776 A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
NCT05150691 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05396794 Bariatric Education for Women With Obesity and Endometrial Cancer
NCT05092373 Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT04569773 Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
NCT05523440 Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT03564340 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT04590326 A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
NCT05990426 Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT05592626 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors
NCT05230186 A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
NCT03065062 Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT05059444 ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT04512144 Mindfulness in Endometrial and Cervical Cancer
NCT06132958 Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT05548296 A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT05646316 Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT04997096 Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT04851119 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT06486441 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT05252416 (VELA) Study of BLU-222 in Advanced Solid Tumors
NCT04774419 Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
NCT05997017 Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT04458402 Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT05691504 Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05712668 Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT06129604 Pilot Window of Opportunity Trial (POET)
NCT04576104 Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT05194072 A Study of SGN-B7H4V in Advanced Solid Tumors
NCT06400472 A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT05112601 Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT06388018 Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
NCT06036836 Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT04485013 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT04604613 Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT05603910 Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT05691010 A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT04291612 Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT05559879 Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT04469764 Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT04839614 Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT05827614 Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
NCT00005095 Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT05256225 Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer
NCT05768139 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT06270706 A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT05640999 Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT03968406 Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT04586959 Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT04044859 ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04527900 The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT04300556 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06518564 Avelumab and M1774 in ARID1A-mutated Endometrial Cancer (Prior IO)
NCT04080284 Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT05049538 Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers
NCT06686043 HPV Vaccine, Imiquimod, and Metformin Combination Trial
NCT03785288 Vaginal Cuff Brachytherapy Fractionation Study
NCT05542407 ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT03932409 Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT04486352 A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT05154487 A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT05758688 PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT06438588 Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
NCT06096688 Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT06366347 ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab
NCT04570553 Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT05564377 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT04683653 Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT05277051 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT06538337 Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
NCT05554328 Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05489211 Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT06172478 A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT04567771 Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT06607185 A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT04008797 A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT05538897 Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT03422198 Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT05705505 Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
NCT04704661 Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT05761951 Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT05787587 A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors

Research Search Tool Sponsored By: